Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q1 2018 · 10-Q
Revenue$6.57M$6.57Mno prior Q1 2017 on file Net Income-$8.44M-$8.44MN/M vs Q1 2017 EPS Diluted-$0.15-$0.15N/M vs Q1 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flow-$3,989,000N/M Free Cash Flowderived-$4,150,000N/M Margins · derivedGross margin47.8%
Operating margin-127.9%
Net margin-128.6%
ended Mar 31, 2018 · filed May 10, 2018 · 40 d after period end